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OBJECTIVES The purpose of this study was to analyze the type of arrhythmia recurrence, based on stored
electrograms, in patients with a healed myocardial infarction (MI) who received an
implantable defibrillator.
BACKGROUND Previous studies suggest that patients presenting with cardiac arrest (CA) tend to recur as
ventricular fibrillation (VF), whereas those suffering sustained monomorphic ventricular
tachycardia (SMVT) tend to recur as SMVT. However, these data have not been confirmed
in a homogeneous population of patients with MI.
METHODS A total of 88 patients was divided into three groups according to their clinical presentation:
SMVT (n 5 57), CA (n 5 16) or syncope (n 5 15).
RESULTS There were no significant differences in clinical characteristics among groups. In the
electrophysiologic study SMVT was induced in 93%, 94% and 80% of patients, respectively
(p 5 NS). During the follow-up period, 52% of patients presented a total of 671 episodes of
ventricular arrhythmia treated by the defibrillator. All recurrences were as SMVT except for
one VF. There were 610 episodes of SMVT treated with antitachycardia pacing, with an
effectiveness of 96%. A total of 61 episodes was treated initially with cardioversion. No
differences in the probability of recurrence were observed among groups, although the
statistical power was low (50%).
CONCLUSIONS In patients with an old infarction and malignant ventricular arrhythmias, the majority of
recurrences are due to SMVT independently of the clinical presentation (SMVT, CA or
syncope) or the induced arrhythmia at the electrophysiologic study. The programming of
an antitachycardia zone seems to be appropriate also for patients who present with CA
or syncope. (J Am Coll Cardiol 1999;34:351–7) © 1999 by the American College of
Cardiology
There are some conflicting data about the influence of
clinical presentation in the type and frequency of recur-
rences in patients suffering sustained ventricular arrhythmias
(1–5). Some studies that analyzed an episode of cardiac
arrest (CA) in patients carrying a Holter recording showed
that the initial arrhythmia leading to CA was sustained
monomorphic ventricular tachycardia (SMVT), which de-
generates into ventricular fibrillation (VF) (3–5). However,
more recent studies, analyzing arrhythmia recurrences in
patients carrying implantable cardiac defibrillators (ICDs),
suggest that patients presenting with CA or syncope had
fewer recurrences than those with SMVT, and that survi-
vors of CA tend to recur as VF as opposed to patients with
SMVT, who recur as ventricular tachycardia (VT) (1,2).
The study by Raitt et al. (1) was done in patients carrying
ICDs without electrogram recording capabilities, raising
some doubts in the interpretation of the arrhythmia recur-
rences. Furthermore, several pathologic substrates of the
arrhythmia were included, which may have led to mislead-
ing information. Knowledge of the type of recurrences
should be a determinant in programming the antitachycar-
dia pacing or in choosing a device with antitachycardia
pacing capability.
The aim of our study was to analyze the influence of
initial arrhythmia in the recurrence of ventricular arrhyth-
mias in patients with a healed myocardial infarction (MI)
who received an ICD with electrogram storage.
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METHODS
Patients
Between January 1992 and February 1997, 166 automatic
implantable defibrillators were implanted at our institution.
Of them, 88 had a healed MI and received an ICD with
electrogram storage. Patients were divided into three groups
according to their clinical presentation: patients with
SMVT (VT group, n 5 57), patients recovered from CA
(CA group, n 5 16) and patients with syncope of unknown
origin and VT/VF induced during the electrophysiologic
study (EPS) (syncope group, n 5 15). None of the patients
had acute MI at the moment of the ventricular arrhythmia,
and a reversible cause that could have precipitated the
arrhythmia was excluded.
Definitions
Clinical presentation. A patient was included in the
SMVT group when there was electrocardiographic (ECG)
documentation of the arrhythmia. Patients were included in
the CA group when the patient presented with CA that
required cardiac resuscitation including defibrillation and
there was no ECG documentation of SMVT. Patients were
included in the syncope group when there was a history of
syncope of unknown origin and inducible ventricular ar-
rhythmias at the EPS.
Analysis of recurrences. Recurrence as SMVT was defined
as a regular tachycardia with uniform electrogram different
from sinus rhythm (Fig. 1). Recurrence as “fast” SMVT was
defined as SMVT with a cycle length between 220 and
300 ms (Fig. 2). Ventricular fibrillation was defined as
polymorphic ventricular arrhythmia with a cycle length of
,220 ms treated with cardiac shock (Fig. 3).
Electrophysiologic Study
All patients underwent an EPS previous to the ICD
implantation. The procedure was done using local anesthe-
sia with a light sedation. All antiarrhythmic drugs were
discontinued for at least 5 drug half-lives except in those
who had been taking amiodarone. The programmed ven-
tricular stimulation was done at the apex of the right
ventricle at three drive train cycle lengths and during sinus
rhythm up to three extrastimuli according to a previously
described protocol (6). Patients were considered “inducible”
when a sustained VT or VF was provoked. The induction of
nonsustained VT (less than 30 s without collapse) was not
considered as inducible arrhythmia.
Implantable Cardioverter Defibrillator
All patients who recovered from CA were considered
candidates for ICD implantation after reversible causes were
independently discarded from the EPS results. Patients
from the SMVT group were treated with an ICD when the
initial VT was syncopal, poorly tolerated due to a presyn-
cope, angina or systolic arterial tension of ,90 mm Hg or
when VT was refractory to antiarrhythmic medication,
including amiodarone. Patients who presented with a syn-
cope received an ICD when during the EPS a sustained
ventricular arrhythmia was induced and no other causes for
syncope were identified using other tests (e.g., echocardio-
gram, Holter recording, tilt test, exercise testing or coronary
Abbreviations and Acronyms
ATP 5 antitachycardia pacing
CA 5 cardiac arrest
ECG 5 electrocardiographic
EPS 5 electrophysiologic study
ICD 5 implantable cardiac defibrillator
MI 5 myocardial infarction
SMVT 5 sustained monomorphic ventricular tachycardia
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
Figure 1. Electrogram recorded by the implantable cardiac defi-
brillator during an episode of “slow” sustained monomorphic
ventricular tachycardia at a rate of 170 beats/min treated effectively
with antitachycardia pacing.
Figure 2. Electrogram recorded by the implantable cardiac defi-
brillator during an episode of “fast” sustained monomorphic
ventricular tachycardia at a rate of 221 beats/min that was treated
effectively with a defibrillator shock of 23 J.
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angiogram). All the devices had the capability of electro-
gram storage. Devices were systematically programmed in
two zones independently from the clinical presentation or
from the arrhythmia induced during the EPS. The first zone
was for the detection of VT with a heart rate cutoff between
180 and 200 beats/min or 10 beats/min below the rate of the
clinical or the induced tachycardia when available. In this
zone the criteria for the detection of “sudden onset” (9%)
and stability (40 ms) were programmed if the device had the
capability. As a safety feature, the sustained rate duration
criteria were activated when available. The efficacy of this
programming has been previously reported (7). In the VT
zone an empiric antitachycardia pacing algorithm was pro-
grammed. The algorithm was not tested with EPS (8). The
therapy in this zone was programmed with two schemes of
antitachycardia pacing (ATP). The first (ATP1) used a
maximum of eight bursts, consisting of sequences of ven-
tricular impulses initiated by four in the first burst to a
maximum of eight (with a step increment of one impulse
each burst), starting at 81% of the tachycardia cycle length,
and with a decrement of 4 ms in the coupling interval from
burst to burst (minimal interval of 200 ms). The second
scheme (ATP2) was delivered if tachycardia was not termi-
nated by ATP1. It consisted of a maximum of eight ramps
with the same number of ventricular impulses (from four to
eight) and the same decrement in coupling interval (4 ms) as
in ATP 1, but with a decrement of 4 ms between the
impulses within the ramp and a decrement of 6 ms in the
initial cycle length from one ramp to the next. The ATP
attempts were delivered until tachycardia was reverted, or up
to a maximum of 60 to 120 s. If ATP was unsuccessful, a
low energy cardioversion was delivered. A second zone was
established for VF or fast VT with a cutoff rate of 200
beats/min with only shock therapy.
Follow-up
Patients were discharged on the third day after implant if
no complications occurred. Device interrogation was per-
formed one month after discharge, at three months and
thereafter every six months, unless the patient had arrhyth-
mic symptoms or device shocks. The arrhythmic episodes
were documented through patient interrogation and from
the electrograms. If the electrograms were not available the
episode was excluded from the analysis. The episodes were
analyzed by two experienced observers to determine the type
of arrhythmia.
Statistical Analysis
Statistical calculations were performed using the SPSS
package (9). The Fisher exact test or the chi-square test was
used for categorical variables. One-way analysis of variance
or the Kruskal–Wallis test were used for comparisons of
continuous variables among the three groups. Survival
curves were plotted using the Kaplan–Meier method and
analyzed by the log-rank test. A value of p less than 0.05 was
considered statistically significant.
RESULTS
Clinical characteristics. The analysis of clinical variables
in the three groups of patients is shown in Table 1. No
differences were observed with regard to age, gender, three-
vessel disease, localization of the infarction, ejection frac-
tion, functional class, previous revascularization surgery and
antiarrhythmic treatment.
Electrophysiologic study. All patients were inducible at
the electrophysiologic testing to a SMVT or VF except one.
In this patient the ICD was implanted because he presented
with a fast, syncopal VT. There were no differences in the
number of extrastimuli required for induction or in the type
of arrhythmia induced in the three groups (Table 2).
The induced SMVT was “slower” in the VT group
(310-ms cycle vs. 247 ms and 266 ms in CA and syncope
groups, respectively) (p , 0.01).
Defibrillators. The implanted devices were the following:
Guidant-CPI (St. Paul, Minnesota) model Ventak PRXII
and III (31 patients), Mini and Mini II (48 patients),
Medtronic (Minneapolis, Minnesota) model Microjewell (4
patients) and Ventritex Contour (St. Jude Medical Ventri-
tex, Sylmar, California) (5 patients). The implant was
abdominal in 32 and thoracic in 56 patients. All individuals
received a single lead. None of them required subcutaneous
patch. There were six complications related to implant (9%):
one pneumothorax, two hematomas in patients who re-
ceived anticoagulation, a cardiogenic shock solved with
medical therapy, a generator extrusion of an abdominal
device that required surgical reimplantation and a late
infection of the pocket with explantation and replacement
of the whole system.
Follow-up. The mean follow-up period was the same for
the three groups (20 6 11, 23 6 15 and 16 6 9 months for
the VT, CA and syncope groups, respectively, p 5 NS).
Five patients died due to a cardiac cause (one of MI and four
of cardiogenic shock). No CAs were observed. A total of 53
Figure 3. Electrogram recorded by the implantable cardiac defi-
brillator during an episode of polymorphic ventricular tachycardia/
fibrillation treated effectively with a defibrillator shock of 20 J.
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patients (60%) required antiarrhythmic therapy during
follow-up to diminish the number of recurrences (Table 3).
The proportion of patients receiving antiarrhythmics was
similar in the three groups. Thirty-six patients (68%)
received amiodarone, 6 (11%) were treated with sotalol and
11 (21%) were treated with atenolol.
During the follow-up period 46 patients (52%) presented
at least one episode of sustained ventricular arrhythmia
detected and treated by the device. A total of 137 episodes
of recurrences that occurred in four patients with electrical
storm were excluded from the analysis because the electro-
grams of the episodes were not available due to memory
saturation. Nevertheless, the episodes analyzed in these four
patients corresponded to SMVT. A total of 671 were
analyzed. All recurrences were SMVT with the exception of
one patient who presented VF (Fig. 3). The induction of VF
during the EPS was not predictive of the recurrence as VF,
because none of the patients induced to VF suffered VF
during the follow-up period (Table 3). However, the induc-
tion of SMVT at the EPS was highly predictive of recur-
rence as SMVT, because all the episodes of recurrence were
as SMVT except one.
When analyzing the probability of recurrence and the
number of episodes per patient, the syncope group showed
a lower percentage, although these differences were not
statistically significant (Fig. 4, Table 3). The statistical
power to detect differences in the probability of recurrence
between the syncope group and the SMVT group was low
(51% for an observed difference among groups of 33%). The
power to detect differences in the number of episodes
between the syncope and the SMVT group was also limited
(68% for a mean number of episodes of 5.5 6 5 vs. 15.8 6
30, respectively). This was due to the small number of
patients and recurrences in the syncope group. The cycle
length of detected VT was not different among the three
groups during the follow-up period (Table 4).
Antitachycardia pacing. Five VT patients (15.2%), one
patient (13%) of the CA group and one patient (15%) of the
syncope group suffered only “fast” VT episodes treated with
direct shock because of the high rate of the tachycardia that
was directly counted in the VF zone of the device (Table 3).
The remaining patients had “fast” and “slow” or only “slow”
tachycardias. Tachycardias detected in the VT zone of the
device were treated with antitachycardia pacing with an
effectiveness of 98%, 91% and 88% for the VT, CA and
Table 2. Characteristics of the Electrophysiologic Study
SMVT
(n 5 57)
Cardiac Arrest
(n 5 16)
Syncope
(n 5 15) p Value
Induced arrhythmia, n (%)
SMVT 53 (93) 15 (94) 12 (80)
Polymorphic VF/VT 3 (5) 1 (6) 3 (20)
Noninducible 1 (2) 0 0 NS
Number of required extrastimuli 2.5 6 0.6 2.6 6 0.5 2.7 6 0.5 NS
Syncopal induced VT 45 (79) 13 (81) 14 (93) NS
Cycle of induced VT (ms) 310 6 73 247 6 50 266 6 85 0.01
Termination of VT by ATP 26 (46) 9 (56) 8 (53) NS
ATP 5 antitachycardia pacing; SMVT 5 monomorphic ventricular tachycardia; VF 5 ventricular fibrillation; VT 5 ventricular
tachycardia.
Table 1. Baseline Patient Characteristics
Patient Characteristics
SMVT
(n 5 57)
Cardiac Arrest
(n 5 16)
Syncope
(n 5 15) p Value
Age (yr) 63 6 7 61 6 14 65 6 5 NS
Male/female 54/3 16/0 14/1 NS
Anterior MI, n (%) 34 (60) 10 (63) 7 (46) NS
Multiple MI, n (%) 13 (23) 7 (44) 3 (20) NS
Functional class, n (%)
I 32 (56) 12 (75) 8 (53)
II 19 (33) 3 (19) 5 (33)
III 6 (11) — 2 (13)
IV — 1 (6) — NS
Ejection fraction (%) 30 6 9 34 6 14 37 6 7 NS
Three-vessel disease, n (%) 14 (25) 6 (38) 2 (13) NS
Aneurysm, n (%) 7 (13) 5 (30) 4 (25) NS
Past coronary bypass graft 6 (11) 3 (11) 2 (13) NS
MI 5 myocardial infarction; SMVT 5 sustained monomorphic ventricular tachycardia.
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syncope groups, respectively (p 5 NS). The efficacy of the
ATP was not significantly different in patients receiving
antiarrhythmic therapy as compared with those who were
not on antiarrhythmics.
DISCUSSION
The introduction of ICDs with the capability to store
electrograms has allowed establishment of the type of
recurrences observed in patients with ventricular arrhyth-
mias. The aim of our study was to analyze the influence of
the clinical presentation on the observed recurrences in a
group of patients with a healed infarction. Contrary to what
has been suggested in a previous study (1), we observed that
patients with ventricular arrhythmias, whose clinical presen-
tation was VT, CA or syncope, did not significantly differ in
the type of recurrence, which was usually SMVT indepen-
dently from its form of presentation and from the induced
arrhythmia at the EPS.
Clinical characteristics. There were no differences among
the three groups in their basal clinical characteristics.
Previous studies have found differences according to clinical
presentation (10), but they have considered several etiolo-
gies, which may have distorted the results. Our data are in
agreement with the findings reported by Stevenson et al.
(11) in patients with healed MI. They only found a higher
percentage of multiple areas of MI in survivors of CA as
compared with those with VT.
Characteristics of the EPS. The three groups presented a
high inducibility to SMVT; this fact is in agreement with
previous studies that observed that a healed infarction was a
powerful predictor of inducibility of SMVT at the EPS
(1,6).
The inducibility to any sustained arrhythmia was 100% in
the syncope group, because this was a requirement in these
patients to receive a defibrillator. However, there was a
100% inducibility at the CA group, which is higher than
Figure 4. Kaplan–Meier curves showing the time-related
arrhythmia-free interval for the three groups of patients (sustained
monomorphic ventricular tachycardia [SMVT], cardiac arrest and
syncope) (log-rank test, p 5 NS).
Table 3. Ventricular Arrhythmias Detected During Follow-up
SMVT
(n 5 57)
Cardiac Arrest
(n 5 16)
Syncope
(n 5 15) p Value
Months of follow-up 20 6 11 23 6 15 16 6 9 NS
Patients with recurrences, n (%) 34 (60) 8 (50) 4 (27)
Type of recurrence, (%)
SMVT 33 (98) 8 (100) 4 (100)
VF 1 (2) 0 0
VT rate (beats/min) 188 6 32 184 6 17 186 6 22 NS
Mean episodes/patient 15 6 29 12 6 18 5 6 5 NS
Fast VT, n (%) 5 (15) 1 (13) 1 (25)
Slow VT 1 fast VT, n (%) 15 (44) 6 (75) 1 (25)
Slow VT, n (%) 14 (41) 1 (13) 2 (50) NS
Mean heart rate fast VT (beats/min) 225 6 21 228 6 24 234 6 22 NS
Total number of episodes 544 107 20
Number of episodes treated
with ATP, n (%)
504 (93) 90 (84) 16 (80) NS
ATP effective, n (%) 493 (98) 82 (91) 14 (88) NS
Patients on antiarrhythmic therapy 36 (63) 11 (69) 6 (40) NS
Abbreviations as in Table 2.
Table 4. Type of Recurrence in Relation to Induced Arrhythmia
at the Electrophysiologic Study
Type of Recurrence
Induced Arrhythmia
SMVT
(n 5 80)
VF
(n 5 7)
Noninducible
(n 5 1)
Recurrence as SMVT,
n (%)
42 (53) 2 (29) 1 (100)
Recurrence as VT
and VF, n (%)
1 (1) 0 0
No recurrence, n (%) 37 (46) 5 (71) 0
Abbreviations as in Table 2.
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that reported in patients recovered from CA. Even in the
study by Brugada et al. (6), in which the same stimulation
protocol was applied to patients with healed infarction
recovered from CA, the inducibility observed was lower
(77%). This may be due to an unwanted bias toward
implantation of the device in inducible patients. On the
other hand, we observed that the induced VT was faster in
the CA and syncope groups as compared with the SMVT
group. This had already been observed by Brugada et al. (6).
However, we did not observe differences in the cycle length
of the recurrences among the three groups. Only two of the
seven patients in whom the induced arrhythmia was VF
recurred during the follow-up, and both presented episodes
of SMVT. Therefore, the induction of VF during the EPS
was not predictive of the type of recurrence, at variance with
what has been reported by Mitra et al. (12). However, the
later report also included patients with diverse underlying
cardiopathies, and this may explain the observed differences.
Type and frequency of recurrences. Classical studies that
analyzed the Holter recording in patients who died suddenly
while wearing the recorder showed that death due to
tachyarrhythmia was often the consequence of a tachycardia
that degenerated into VF (3–5). These data are coincident
with our observations. However, a recent study by Raitt et
al. suggests that survivors of CA tend to have recurrences as
VF, whereas those suffering SMVT tend to recur as VT (1).
Several facts may explain this apparent discordance. First of
all, this study included patients with several cardiopathies
(from normal hearts to dilated cardiomyopathies). It is well
known that patients with a healed infarction have a different
underlying mechanism of the arrhythmia than patients with
normal heart or other cardiopathies, and that they tend to
have arrhythmias based on stable reentry circuits within the
infarcted zone (13). Our data support the concept that in
patients with healed infarction without acute reinfarction,
the recurrent arrhythmias are initially SMVT. A second
difference from the study by Raitt et al. (1) is that the latter
was performed with devices without electrogram storage,
which may have led to misclassification of some cases of fast
VT as VF.
In our study we have not observed significant differences
in the probability of recurrence or in the number of episodes
per patient between the three groups. Menz et al. (2), in a
similar analysis, found a higher probability of recurrence in
patients presenting with SMVT. However, his series in-
cluded several etiologies that may greatly influence the
results, as we have already pointed out.
Antitachycardia therapy. The majority of episodes of
SMVT were treated with antitachycardia pacing with high
effectiveness in the three groups. The percentage of episodes
of “fast” VT not amenable to antitachycardia pacing was
similar among the three groups. According to these obser-
vations, the use of the empirical antitachycardia algorithm is
recommendable in the three groups, and there is no need to
perform a predischarge EPS to test the efficacy of the
algorithm.
Observations in patients with syncope of unknown eti-
ology and healed infarction. Patients with syncope as the
presenting symptom showed similar clinical characteristics
and results at the EPS. There were no differences with the
other groups in the type and probability of recurrence.
However, there seems to be a tendency toward a lower
number of recurrences, although not significant, due pre-
sumably to the small number of patients in this group. Link
et al. (14) have observed a significant percentage (22%) of
appropriate therapies of the ICD in patients with syncope
and inducible arrhythmias after a short follow-up. We have
recently published data showing that all patients who
completed one year of follow-up received appropriate ther-
apy (15). All of these data strongly support the use of
defibrillator with antitachycardia pacing in these patients,
despite the lack of ECG recording of the index episode.
Clinical implications for the use of ICDs. Several vari-
ables are well known as predictive of therapy by the ICD,
among them the depressed ejection fraction, the inducibility
to SMVT and the number of extrastimuli required for
induction (16,17). However, the importance of the under-
lying cardiopathy in determining the type of recurrence has
not been emphasized. The fact that patients with healed
MI tend to recur as SMVT independently of the clinical
presentation or the induced arrhythmia has important
consequences in choosing the kind of device and the
subsequent programming. According to our findings, pa-
tients with malignant ventricular arrhythmias and healed
infarction should receive an ICD with antitachycardia
pacing programming even if the clinical presentation was
VF, or VT was not induced at the EPS.
Study limitations. The small number of patients in the CA
and syncope groups may be the reason that no significant
differences in the probability of recurrence between groups
were observed; in fact, the statistical power to detect
meaningful differences in the probability of recurrences and
in the number of recurrences was 51% and 68%, respec-
tively. However, this would not affect the main finding in
the study that in patients with healed infarction and
malignant ventricular arrhythmias, recurrences occur as
SMVT independently of the clinical presentation.
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